Precision Medicine in Prostate Cancer

Precision Medicine in Prostate Cancer

High Activity Pain Reduction and Low Toxicity with Lu177 PSMA617 Theranostics - Michael Hofman

December 27, 2019

Details

Precision Medicine in Prostate Cancer

The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris

November 18, 2019

Details

Precision Medicine in Prostate Cancer

177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer - Oliver Sartor

October 31, 2019

Details

Precision Medicine in Prostate Cancer

A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor

October 14, 2019

Details

Precision Medicine in Prostate Cancer

PROfound Study - PARP-inhibitor Olaparib in Advanced Prostate Cancer Patients with Specific Tumor Mutations - Maha Hussain

October 10, 2019

Details

Precision Medicine in Prostate Cancer

PSMA Targeted Therapies Presentation - Michael Hofman

September 18, 2019

Details

Precision Medicine in Prostate Cancer

State of the Art: Treatment Update in Prostate Cancer- Oliver Sartor

November 2, 2018

Details